CAR T-cell therapy has shown promising results for certain types of leukemia and lymphoma. Here are some key points based on my knowledge base:
- Success Stories: Some individuals, like Olson, have experienced long-term remission. Olson, who had chronic lymphocytic leukemia (CLL), remained in remission for over 10 years Show Full Answer
CAR T-cell therapy has shown promising results for certain types of leukemia and lymphoma. Here are some key points based on my knowledge base:
- Success Stories: Some individuals, like Olson, have experienced long-term remission. Olson, who had chronic lymphocytic leukemia (CLL), remained in remission for over 10 years and is now a distance runner and fundraiser.
- Side Effects: CAR T-cell therapy can cause cytokine-release syndrome (CRS), which includes symptoms like nausea, fatigue, headache, chills, and fever. Severe CRS can lead to low blood pressure, rapid heartbeat, cardiac arrest, and kidney issues, sometimes requiring intensive care.
- Effectiveness: Clinical trials have shown remission rates of up to 94% in difficult-to-treat B-cell leukemias. However, not all recipients achieve remission.
- FDA-Approved Therapies: Several CAR T-cell therapies are FDA-approved, including:
- Kymriah (tisagenlecleucel): For children and young adults with relapsed or refractory B-cell precursor ALL and adults with certain types of relapsed or refractory B-cell lymphoma.
- Tecartus (brexucabtagene autoleucel): For adults with relapsed or refractory mantle cell lymphoma and B-cell ALL.
- Yescarta (axicabtagene ciloleucel): For adults with types of relapsed or refractory large B-cell lymphoma and follicular lymphoma.
It's important to discuss potential risks and benefits with your healthcare provider.
September 7, 2024
Join
Your Privacy Choices
